The past 200 years in diabetes.

@article{Polonsky2012TheP2,
  title={The past 200 years in diabetes.},
  author={K. Polonsky},
  journal={The New England journal of medicine},
  year={2012},
  volume={367 14},
  pages={
          1332-40
        }
}
  • K. Polonsky
  • Published 2012
  • Medicine
  • The New England journal of medicine
Although scientific advances have led to effective prevention strategies, the pathway to a cure for diabetes has remained elusive. This anniversary article describes progress in the understanding, diagnosis, and management of diabetes during the past 200 years. 

Figures, Tables, and Topics from this paper

Preface: A New Disease?
TLDR
Professor Gian Franco Bottazzo delivered the Banting Lecture, in which he announced that diabetes was “a new disease,” based on criteria originally described by Mirko D. Grmek in his classical book about the history of AIDS. Expand
The role of mast cells in type I diabetes mellitus
Scientific Advisor – MD, PhD, Associate Professor Lilian Şaptefraţi Department of Histology, Cytology and Embryology, USMF “Nicolae Testemiţanu”
The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years
TLDR
A stabilization in the rate of end stage kidney disease has been observed in some countries, probably due to the increased awareness by primary care physicians about the prognostic importance of chronic kidney disease (CKD), better control of blood pressure and glycaemia. Expand
J. Clin. Med
  • 2015
Challenge of diabetes mellitus and researchers’ contributions to its control
Abstract The aim of this review study was to assess the past significant events on diabetes mellitus, transformations that took place over the years in the medical records of treatment, countriesExpand
Treatment approach to type 2 diabetes: Past, present and future
TLDR
Given the raising burden of type 2 DM, the best present strategy that could contribute the most to the reduction of morbidity and mortality should be focused on primary prevention. Expand
An update on the pharmacotherapy options for pediatric diabetes
TLDR
This review offers an update on current available treatment strategies for type 1 and type 2 diabetes approved for use in children and adolescents, with a strong need for developing new drugs to be used alone or in combination. Expand
Tracing the proteomic fingerprint of the diabetic aorta?
TLDR
Although there is compelling evidence for the association of diabetes mellitus and vascular disease, the underlying pathophysiological mechanisms remain to be elucidated, and advanced glycation end products as well as reactive oxygen species are suggested to be 2 of the major culprits leading to vascular damage. Expand
Islet cell transplantation.
TLDR
While islet transplantation is currently generally reserved for adults with type 1 diabetes with severe hypoglycemia or glycemic lability, the possibility of its application to the pediatric population is considered. Expand
Cardiovascular Safety Evaluation in the Development of New Drugs for Diabetes Mellitus
TLDR
The burden of type 2 diabetes mellitus across the United States continues to increase, and the current dramatic increase in the prevalence is a harbinger for increasing cardiovascular morbidity and mortality in the decades ahead. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
Effect of a multifactorial intervention on mortality in type 2 diabetes.
TLDR
In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes. Expand
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
TLDR
Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria, and serious adverse events were less frequent among the patients treated with the drug. Expand
Pioglitazone for diabetes prevention in impaired glucose tolerance.
TLDR
As compared with placebo, pioglitazone reduced the risk of conversion of impaired glucose tolerance to type 2 diabetes mellitus by 72% but was associated with significant weight gain and edema. Expand
[The discovery of insulin].
  • H. Lestradet
  • History, Medicine
  • Bulletin de l'Academie nationale de medecine
  • 1996
TLDR
It seems necessary, seventy five years later, to reconsider the chronology of the history and put Paolesco but also Collip at the right places much before Banting and Best to whom, by a curious misinterpretation of facts, was attributed the priority of this fundamental discovery. Expand
Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young.
Maturity-onset diabetes of the young (MODY) is a clinically heterogeneous group of disorders characterized by nonketotic diabetes mellitus, an autosomal dominant mode of inheritance, an onset usuallyExpand
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
TLDR
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone. Expand
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
TLDR
A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent. Expand
HL-A antigens and diabetes mellitus.
TLDR
The increase of HL-A8 in insulin-dependent diabetes, Graves' disease, and idiopathic Addison's disease is suggestive of a common pathogenesis of these endocrine autoimmune conditions. Expand
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
TLDR
Intensive diabetes therapy has long-term beneficial effects on the risk of cardiovascular disease in patients with type 1 diabetes, and changes between treatment groups remained significant after adjusting for these factors. Expand
Genomics of type 2 diabetes mellitus: implications for the clinician
TLDR
The current list of genetic loci that are related to T2DM does not seem to offer greater predictive value in determining diabetes risk than do commonly used phenotypic risk factors and family history. Expand
...
1
2
3
4
5
...